Nicholas Trakul, MD, PhD, Jeremy P

Slides:

Advertisements

Similar presentations

Vertebral Fractures After Stereotactic Ablative Radiotherapy of Lung Tumors Todd A. Aguilera MD PhD 1, Nicholas Trakul MD PhD 2, David B. Shultz MD PhD.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Jeffrey Bradley, MD Journal of Thoracic Oncology

Image–Guided Radiation Therapy for Non–small Cell Lung Cancer

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study Thomas.

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer Patrick Wald,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non–Small Cell Lung Cancer Hann-Hsiang.

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci,

Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non–Small Cell Lung Cancer: A Phase I Study Kristin A. Higgins,

Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer Margaret.

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Jeffrey Bradley, MD Journal of Thoracic Oncology

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer:

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Debby P. M. van den Bogaert, MD, Ellen M

Stereotactic Body Radiotherapy for Central Lung Tumors

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC Sara Ramella, MD, Michele.

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors Nicholas Trakul, MD, PhD, Jeremy P. Harris, BS, MPhil, Quynh-Thu Le, MD, Wendy Y. Hara, MD, Peter G. Maxim, PhD, Billy W. Loo, MD, PhD, Maximilian Diehn, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 9, Pages 1462-1465 (September 2012) DOI: 10.1097/JTO.0b013e31825f22ce Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Outcomes of SABR reirradiation after local recurrence. A, Kaplan-Meier estimates of LC for reirradiated tumors (black line), compared with the control group of tumors that had not received prior irradiation (gray line). B, Kaplan-Meier estimates of progression-free survival of reirradiated (black line) and control (gray line) patients. C, Kaplan-Meier estimates of overall survival (OS) of reirradiated (black line) and control (gray line) patients. D, Kaplan-Meier estimates of LC for reirradiated tumors with time to retreatment (TTR) ⩽ 16 months (black line) or TTR > 16 months (gray line). The median TTR in this cohort was 16 months. LC, local control. Journal of Thoracic Oncology 2012 7, 1462-1465DOI: (10.1097/JTO.0b013e31825f22ce) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Example of SABR reirradiation for a patient with local recurrence after an initial course of SABR. A, First treatment course of SABR for a right lower lobe non–small-cell lung cancer. Prescribed dose was 50 Gy in four fractions. B, Second course of SABR after biopsy confirmed local progression. Prescribed dose was 20 Gy in a single fraction. Volumes: orange shading = gross tumor volume, red shading = planning target volume. Isodose curves: magenta 50%, yellow 100%, and cyan 110% of prescription dose. C, Six-month follow-up positron emission tomography/computed tomography scan showing shrinkage, metabolic response, and mild local inflammation. SABR, stereotactic ablative radiotherapy. Journal of Thoracic Oncology 2012 7, 1462-1465DOI: (10.1097/JTO.0b013e31825f22ce) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions